INCYTE CORP (1INCY.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1INCY - US45337C1027 - Common Stock
1INCY.MI Key Statistics, Chart & Performance
The current stock price of 1INCY.MI is 88.44 EUR.
1INCY.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 74.26 | 49.11B | ||
| ARGX.BR | ARGENX SE | 74.25 | 49.10B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.87B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.70B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.69B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.76B | ||
| 5CV.DE | CUREVAC NV | 5.31 | 1.04B | ||
| NANO.PA | NANOBIOTIX | N/A | 822.55M | ||
| PHIL.MI | PHILOGEN SPA | 20.96 | 698.84M | ||
| IVA.PA | INVENTIVA SA | N/A | 541.14M | ||
| ALCLS.PA | CELLECTIS | N/A | 440.93M | ||
| FYB.DE | FORMYCON AG | N/A | 438.22M |
Related stock screener links
About 1INCY.MI
Company Profile
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,524 full-time employees. The firm operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.
Company Info
INCYTE CORP
1801 Augustine Cut-Off
Wilmington DELAWARE US
Employees: 2524
Phone: 13024986700
INCYTE CORP / 1INCY.MI FAQ
Can you describe the business of INCYTE CORP?
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,524 full-time employees. The firm operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.
What is the current price of 1INCY stock?
The current stock price of 1INCY.MI is 88.44 EUR. The price decreased by -2.49% in the last trading session.
What is the dividend status of INCYTE CORP?
1INCY.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1INCY stock?
1INCY.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the valuation of INCYTE CORP (1INCY.MI) based on its PE ratio?
The PE ratio for INCYTE CORP (1INCY.MI) is 104.05. This is based on the reported non-GAAP earnings per share of 0.85 and the current share price of 88.44 EUR.
What is the ownership structure of INCYTE CORP (1INCY.MI)?
You can find the ownership structure of INCYTE CORP (1INCY.MI) on the Ownership tab.
1INCY.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1INCY.MI.
1INCY.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1INCY.MI. 1INCY.MI has an excellent profitability rating, but there are some minor concerns on its financial health.
1INCY.MI Financial Highlights
Over the last trailing twelve months 1INCY.MI reported a non-GAAP Earnings per Share(EPS) of 0.85. The EPS decreased by -62.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.52% | ||
| ROA | 2.09% | ||
| ROE | 3.25% | ||
| Debt/Equity | 0.01 |
1INCY.MI Forecast & Estimates
31 analysts have analysed 1INCY.MI and the average price target is 67.15 EUR. This implies a price decrease of -24.08% is expected in the next year compared to the current price of 88.44.
For the next year, analysts expect an EPS growth of -55% and a revenue growth 12.38% for 1INCY.MI